News articles about KalVista Pharmaceuticals (NASDAQ:KALV) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. KalVista Pharmaceuticals earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.2047846869577 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Separately, BTIG Research raised their price target on KalVista Pharmaceuticals from $18.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, October 16th.

KalVista Pharmaceuticals (KALV) opened at $9.15 on Monday. KalVista Pharmaceuticals has a 12-month low of $5.48 and a 12-month high of $15.80. The stock has a market capitalization of $89.86 and a PE ratio of -3.75.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, December 14th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.05). KalVista Pharmaceuticals had a negative net margin of 1,379.58% and a negative return on equity of 70.20%. The business had revenue of $1.13 million during the quarter.

In other KalVista Pharmaceuticals news, major shareholder Holdings A/S Novo sold 2,725,283 shares of KalVista Pharmaceuticals stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $9.64, for a total value of $26,271,728.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Rajeev M. Shah bought 850,000 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was acquired at an average price of $8.50 per share, for a total transaction of $7,225,000.00. The disclosure for this purchase can be found here. Insiders own 49.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect KalVista Pharmaceuticals (KALV) Stock Price” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/25/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-kalvista-pharmaceuticals-kalv-stock-price.html.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

Insider Buying and Selling by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)

Receive News & Stock Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related stocks with our FREE daily email newsletter.